Manipulation of Arterial Pressure in Acute Ischemic Stroke (MAPAS)
Primary Purpose
Stroke, Acute
Status
Unknown status
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)
Esmolol, NPS or NOR
manipulation of SAP
Sponsored by
About this trial
This is an interventional treatment trial for Stroke, Acute focused on measuring Stroke, Acute, Systolic Pressure of Blood
Eligibility Criteria
Inclusion Criteria:
- Patients 18 years or older, with the first Acute Ischemic Stroke within the first 6 hours of the symptoms and not candidate to thrombolysis
- We will also include patients with previous Ischemic Stroke with Ranking score 0 or 1
Exclusion Criteria:
- Improuvment of the symptoms rapidly (in the first 15 min after admission)
- Seizures not related do the acute ischemic stroke
- Previous ischemic stroke in the last 6 weeks and with Ranking score > 1
- Haemorrhagic stroke
- Anticoagulation
- Hypoglycemia
- Shock
- Acute heart failure
Sites / Locations
- Hospital de Clínicas de Porto Alegre/ UFRGSRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
1, 140 to 160 mmHg
2, 161 to 180 mmHg
3, 181 to 200 mmHg
Arm Description
Esmolol, NPS or NOR
Esmolol, NPS or NOR
Esmolol, NPS or NOR
Outcomes
Primary Outcome Measures
Ranking score and mortality
Secondary Outcome Measures
Full Information
NCT ID
NCT00848770
First Posted
February 19, 2009
Last Updated
December 30, 2009
Sponsor
Hospital de Clinicas de Porto Alegre
1. Study Identification
Unique Protocol Identification Number
NCT00848770
Brief Title
Manipulation of Arterial Pressure in Acute Ischemic Stroke
Acronym
MAPAS
Official Title
Manipulation of Arterial Pressure Early in Non Thrombolysed Acute Ischemic Stroke: Effects on Death and Neurological Disability
Study Type
Interventional
2. Study Status
Record Verification Date
February 2009
Overall Recruitment Status
Unknown status
Study Start Date
January 2008 (undefined)
Primary Completion Date
December 2010 (Anticipated)
Study Completion Date
December 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Hospital de Clinicas de Porto Alegre
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a controlled clinical trial among non thrombolysed acute ischemic stroke patients to determine the effects of three levels of arterial pressure on death and neurological disability. After the admission in the vascular unit of the Emergency Department the patients are randomized to maintain during the first 24h the Systolic Arterial Pressure in tree levels of pressure: 140 to 160 mmHg; 161 to 180 mmHg and 181 to 200 mmHg. The end point of the study is the Modified Rankin score and mortality in three month after the discharge.
Detailed Description
To maintain the tree levels of systolic arterial pressure during de first 24h we will use one of the two strategies:1) infusion of 500 to 1000ml of saline solution and/or norepinephrine solution to increase de systolic pressure or 2) infusion of esmolol or nitroprussiate solution to decrease de pressure. Every patient will have a transcranial doppler study in the first 24h to measure the mean velocity of cerebral arteries.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute
Keywords
Stroke, Acute, Systolic Pressure of Blood
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
240 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1, 140 to 160 mmHg
Arm Type
Active Comparator
Arm Description
Esmolol, NPS or NOR
Arm Title
2, 161 to 180 mmHg
Arm Type
Active Comparator
Arm Description
Esmolol, NPS or NOR
Arm Title
3, 181 to 200 mmHg
Arm Type
Active Comparator
Arm Description
Esmolol, NPS or NOR
Intervention Type
Drug
Intervention Name(s)
Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)
Other Intervention Name(s)
Esmolol, NPS or NOR
Intervention Description
Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).
NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.
NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.
Intervention Type
Drug
Intervention Name(s)
Esmolol, NPS or NOR
Intervention Description
We use one of the three drug to manipulate the systolic arterial pressure
Intervention Type
Drug
Intervention Name(s)
manipulation of SAP
Other Intervention Name(s)
Esmolol or NPS or NOR
Intervention Description
Esmolol or NPS or NOR
Primary Outcome Measure Information:
Title
Ranking score and mortality
Time Frame
Three month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients 18 years or older, with the first Acute Ischemic Stroke within the first 6 hours of the symptoms and not candidate to thrombolysis
We will also include patients with previous Ischemic Stroke with Ranking score 0 or 1
Exclusion Criteria:
Improuvment of the symptoms rapidly (in the first 15 min after admission)
Seizures not related do the acute ischemic stroke
Previous ischemic stroke in the last 6 weeks and with Ranking score > 1
Haemorrhagic stroke
Anticoagulation
Hypoglycemia
Shock
Acute heart failure
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Luiz A Nasi, Physician
Phone
55 51 9982 18 44
Email
lnasi@terra.com.br
First Name & Middle Initial & Last Name or Official Title & Degree
Miguel Gus
Phone
55 51 81627002
Email
mgus@mgus.com.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luiz A Nasi, Physician
Organizational Affiliation
Hospital de Clínicas de Porto Alegre / UFRGS
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de Clínicas de Porto Alegre/ UFRGS
City
Porto Alegre
State/Province
RS
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
L A Nasi, Doctor
First Name & Middle Initial & Last Name & Degree
M Gus, Doctor
12. IPD Sharing Statement
Citations:
PubMed Identifier
15716709
Citation
Potter J, Robinson T, Ford G, James M, Jenkins D, Mistri A, Bulpitt C, Drummond A, Jagger C, Knight J, Markus H, Beevers G, Dewey M, Lees K, Moore A, Paul S; CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: rationale and design. J Hypertens. 2005 Mar;23(3):649-55. doi: 10.1097/01.hjh.0000160224.94220.e7.
Results Reference
result
Links:
URL
http://clinicaltrials.gov/ct2/show/NCT00848770
Description
Clinical trial of Manipulation of Arterial Pressure Early in Acute Ischemic Stroke
Learn more about this trial
Manipulation of Arterial Pressure in Acute Ischemic Stroke
We'll reach out to this number within 24 hrs